RTTNews) - Peregrine Pharmaceuticals Inc. (PPHM | charts | news | PowerRating) on Tuesday revealed the selection of final data from its Phase Ib study of bavituximab in patients with chronic hepatitis C viral or HCV infection for an oral presentation at The Liver Meeting 2007.
The company said it believes that bavituximab represents a unique approach with significant clinical promise for treating chronic hepatitis C virus infections.
Bavituximab is the first investigational agent in a new class of anti-phosphotidylserine monoclonal antibodies that targets and binds to cellular components that are normally not present on the outside of cells, but that become exposed on certain virally infected cells and on the surface of enveloped viruses.
read more
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment